The discrepancy in the sensitivity of vimentin antibodies to detect truncated forms in different models, such as hiPSC-derived neurons, postmortem PD brains, and synucleinopathy mouse models, may result from variations in truncation sites, protease involvement, and the degree of vimentin cleavage in each system. Here, VIM is linked to Parkinson disease.